2016
DOI: 10.1007/s00059-016-4482-9
|View full text |Cite
|
Sign up to set email alerts
|

Vasopressin receptor antagonists in patients with chronic heart failure

Abstract: In this brief review, the pathophysiology of hyponatremia and its clinical significance in the course of chronic heart failure (CHF) are illustrated. Moreover, issues concerning the optimal treatment for hyponatremia during CHF are addressed and discussed. In addition, advantages and limitations resulting from the use of vasopressin receptor antagonists, drugs that have recently emerged as the best available resource against hyponatremia, are highlighted.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
2
0

Year Published

2018
2018
2024
2024

Publication Types

Select...
4
1

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(2 citation statements)
references
References 32 publications
0
2
0
Order By: Relevance
“…Nevertheless, the literature contains suggestions for treating hyponatremia during various diseases, mainly heart failure, cardiovascular failure using receptor blockers in the kidneys of vasopressin hormone (antidiuretic hormone) (Greenberg, 2010;Sahay & Sahay, 2014;De Vecchis et al, 2017). However, as our work suggests, the treatment and especially liquidation of the causes (if possible) may be the most effective means of treating hyponatremia.…”
Section: Discussionmentioning
confidence: 91%
“…Nevertheless, the literature contains suggestions for treating hyponatremia during various diseases, mainly heart failure, cardiovascular failure using receptor blockers in the kidneys of vasopressin hormone (antidiuretic hormone) (Greenberg, 2010;Sahay & Sahay, 2014;De Vecchis et al, 2017). However, as our work suggests, the treatment and especially liquidation of the causes (if possible) may be the most effective means of treating hyponatremia.…”
Section: Discussionmentioning
confidence: 91%
“…Following publication, concerns were brought to the attention of the publisher regarding potential redundancy with a previous publication [ 2 ] from the same authorship group.…”
mentioning
confidence: 99%